Hans G. Koebe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hans G. Koebe has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
F W Schildberg
4 shared publicationsS A Pahernik
2 shared publicationsW E Thasler
2 shared publicationsC.J. Deglmann
Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University, D-81366 Munich, Germany
1 shared publicationF. W. Schildberg
Klinikum Großhadern
1 shared publicationF.W. Schildberg
Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University, D-81366 Munich, Germany
1 shared publication
Latest Publications
- 1 November 2000
- Published by Elsevier in Toxicology
- Vol. 154 (1-3) , 31-44
In vitro toxicology in hepatocyte bioreactors-extracellular acidification rate (EAR) in a target cell line indicates hepato-activated transformation of substrates
- 1 November 2000
- Published by Elsevier in Toxicology
- Vol. 154 (1-3) , 31-44
In vitro toxicology in hepatocyte bioreactors-extracellular acidification rate (EAR) in a target cell line indicates hepato-activated transformation of substrates
- 4 September 1998
- Vol. 110 (16) , 551-63
[The artificial liver--an interim report].
A Bioartificial Liver (BAL) is not available to date. Human therapeutic applications of different systems of BAL as of 1998 are presented and discussed. It is concluded that--as for now--no artificial liver device has gained any importance for the treatment of liver failure, and that some critical issues in this field of research have not been sufficiently investigated and/or are not resolved. This review analyzes reports of clinical applications of BAL from the following research groups (numbers in brackets indicate patients treated with an artificial liver device): Demetriou/Rozga, Los Angeles (31 patients), Williams, London (1 patient); Gerlach, Berlin (1 patient); Strom, Virginia (5 patients). The BAL systems used in these studies cannot be directly compared because there are considerable differences in the quality and in quantity of the functional unit employed in bioreactors, the experimental design, patient selection, to mention just a few points. None of the systems investigated so far could convincingly prove its effectivity in replacing impaired liver function neither in animal models nor in a clinical application. It remains to be shown, whether liver cells cultured in bioreactors remain stable, i.e. viable and functionally active, for a sufficient period of treatment. Selected metabolic or detoxifying functions of the bioreactor are difficult to assess, since these functions do not necessarily serve as pars pro toto for the complex clinical presentation of liver failure and therefore cannot sufficiently validate any organ replacement system. Furthermore, since some applications combine biological units with other components, such as active charcoal, it be-comes even more difficult to assess the role of hepatocytes in these settings. Case reports of patients treated with BAL usually refer to BAL as a "successful bridge to transplant", thereby demonstrating the positive effect of orthotopic/auxiliary liver transplants in the treatment of acute liver failure rather than the potential benefit derived from an artificial liver device. Randomised studies have been proposed and urged for years in order to prove the effectivity of these systems which, in part, are already available for clinical use. Because of the heterogeneous patient group in question the design of such protocols will be a difficult task. It must be asked, whether currently used artificial liver systems have left basic science research too early; the use of "black box" applications in humans cannot draw its legitimation merely from the fact that an effective conservative treatment of liver failure is not available so far.
- 4 September 1998
- Vol. 110 (16) , 551-63
[The artificial liver--an interim report].
A Bioartificial Liver (BAL) is not available to date. Human therapeutic applications of different systems of BAL as of 1998 are presented and discussed. It is concluded that--as for now--no artificial liver device has gained any importance for the treatment of liver failure, and that some critical issues in this field of research have not been sufficiently investigated and/or are not resolved. This review analyzes reports of clinical applications of BAL from the following research groups (numbers in brackets indicate patients treated with an artificial liver device): Demetriou/Rozga, Los Angeles (31 patients), Williams, London (1 patient); Gerlach, Berlin (1 patient); Strom, Virginia (5 patients). The BAL systems used in these studies cannot be directly compared because there are considerable differences in the quality and in quantity of the functional unit employed in bioreactors, the experimental design, patient selection, to mention just a few points. None of the systems investigated so far could convincingly prove its effectivity in replacing impaired liver function neither in animal models nor in a clinical application. It remains to be shown, whether liver cells cultured in bioreactors remain stable, i.e. viable and functionally active, for a sufficient period of treatment. Selected metabolic or detoxifying functions of the bioreactor are difficult to assess, since these functions do not necessarily serve as pars pro toto for the complex clinical presentation of liver failure and therefore cannot sufficiently validate any organ replacement system. Furthermore, since some applications combine biological units with other components, such as active charcoal, it be-comes even more difficult to assess the role of hepatocytes in these settings. Case reports of patients treated with BAL usually refer to BAL as a "successful bridge to transplant", thereby demonstrating the positive effect of orthotopic/auxiliary liver transplants in the treatment of acute liver failure rather than the potential benefit derived from an artificial liver device. Randomised studies have been proposed and urged for years in order to prove the effectivity of these systems which, in part, are already available for clinical use. Because of the heterogeneous patient group in question the design of such protocols will be a difficult task. It must be asked, whether currently used artificial liver systems have left basic science research too early; the use of "black box" applications in humans cannot draw its legitimation merely from the fact that an effective conservative treatment of liver failure is not available so far.
- 1 April 1995
- Vol. 41 (2) , 189-93
Porcine hepatocytes from slaughterhouse organs. An unlimited resource for bioartificial liver devices.
Most recent strategies for the development of hybrid artificial liver devices focus on the use of parenchymal liver cells (hepatocytes). For clinical application of these devices, a sufficient cell supply is mandatory. Because human liver tissue is rarely available, isolated porcine hepatocytes from laboratory animals have been suggested for use in bioartificial livers. The authors introduce a modified isolation protocol to yield large scale numbers of viable porcine hepatocytes from slaughterhouse organs. Perfusion and enzymatic digestion of the left medial liver lobe (n = 74) resulted in 1.0 +/- 0.3 x 10(7) viable hepatocytes per gram of tissue, and an overall yield of 1.92 +/- 0.5 x 10(9) viable cells per isolation (viability: 93 +/- 2%). Collagen gel immobilization maintained morphologic integrity and functional activity of hepatocyte cultures over long-term periods. Cell morphology, as assessed by light microscopic evaluation, was maintained for 2 weeks. Stable DNA content (51 +/- 5 micrograms) and low values of alanine aminotransferase release (8 microU/hr/micrograms DNA) indicated structural stability of cultures after a short period of post isolational adaptation. Albumin secretion (4.5 micrograms/hr/micrograms DNA) and persistent Cytochrome P450 IA1 dependent deethylation of 7-ethoxycoumarin (4.5 nmol/hr/micrograms DNA) indicated long-term metabolic activity of cultured hepatocytes. Hepatocytes from livers of slaughtered pigs represent an unlimited resource of viable material for cell culture, and their usefulness as functional units of bioartificial liver support devices should be tested.
- 1 April 1995
- Vol. 41 (2) , 189-93
Porcine hepatocytes from slaughterhouse organs. An unlimited resource for bioartificial liver devices.
Most recent strategies for the development of hybrid artificial liver devices focus on the use of parenchymal liver cells (hepatocytes). For clinical application of these devices, a sufficient cell supply is mandatory. Because human liver tissue is rarely available, isolated porcine hepatocytes from laboratory animals have been suggested for use in bioartificial livers. The authors introduce a modified isolation protocol to yield large scale numbers of viable porcine hepatocytes from slaughterhouse organs. Perfusion and enzymatic digestion of the left medial liver lobe (n = 74) resulted in 1.0 +/- 0.3 x 10(7) viable hepatocytes per gram of tissue, and an overall yield of 1.92 +/- 0.5 x 10(9) viable cells per isolation (viability: 93 +/- 2%). Collagen gel immobilization maintained morphologic integrity and functional activity of hepatocyte cultures over long-term periods. Cell morphology, as assessed by light microscopic evaluation, was maintained for 2 weeks. Stable DNA content (51 +/- 5 micrograms) and low values of alanine aminotransferase release (8 microU/hr/micrograms DNA) indicated structural stability of cultures after a short period of post isolational adaptation. Albumin secretion (4.5 micrograms/hr/micrograms DNA) and persistent Cytochrome P450 IA1 dependent deethylation of 7-ethoxycoumarin (4.5 nmol/hr/micrograms DNA) indicated long-term metabolic activity of cultured hepatocytes. Hepatocytes from livers of slaughtered pigs represent an unlimited resource of viable material for cell culture, and their usefulness as functional units of bioartificial liver support devices should be tested.
- 1 January 1995
- Published by Springer Nature in Surgery Today
- Vol. 25 (1) , 1-10
Surgical treatment of tumor metastases: General considerations and results
The prerequisite for a curative resection of metastases is their restriction to the key organs, the liver and lungs, in the sense of a limited dissemination. For long-term prognosis, the type of primary tumor as well as the radical resection of lung and liver metastases is essential. To improve the process of surgical indication and therapy of tumors, clear definitions for the terms “tumor recurrence” and “metastases” have been agreed upon. Research and clinical investigation have led to a better understanding of tumor-regulating factors, some of which are briefly described: Metastasis promoting factors include the lack of E-cadherin, which leads to a local penetration of basal membranes by tumor cells; CD44 seems to play an important role in cell-cell and cell-matrix interactions, apparently increasing the metastatic potential of tumors and reducing the long-term survival of patients. High levels of urokinase in primary tumors are also associated with a poorer prognosis, as well as plasminogen inactivator inhibitor PAI II, which plays a crucial role in tumor growth. Positive findings in bone marrow aspirates of patients with different malignancies, stained for cytokeratin 18, either are associated with higher recurrence rates in colon and breast cancer or can be correlated to the prognosis of patients with gastric cancer. Technical aspects of surgery for hepatic, pulmonary and skeletal metastases are presented and discussed with respect to curative and palliative indications.
- 1 January 1995
- Published by Springer Nature in Surgery Today
- Vol. 25 (1) , 1-10
Surgical treatment of tumor metastases: General considerations and results
The prerequisite for a curative resection of metastases is their restriction to the key organs, the liver and lungs, in the sense of a limited dissemination. For long-term prognosis, the type of primary tumor as well as the radical resection of lung and liver metastases is essential. To improve the process of surgical indication and therapy of tumors, clear definitions for the terms “tumor recurrence” and “metastases” have been agreed upon. Research and clinical investigation have led to a better understanding of tumor-regulating factors, some of which are briefly described: Metastasis promoting factors include the lack of E-cadherin, which leads to a local penetration of basal membranes by tumor cells; CD44 seems to play an important role in cell-cell and cell-matrix interactions, apparently increasing the metastatic potential of tumors and reducing the long-term survival of patients. High levels of urokinase in primary tumors are also associated with a poorer prognosis, as well as plasminogen inactivator inhibitor PAI II, which plays a crucial role in tumor growth. Positive findings in bone marrow aspirates of patients with different malignancies, stained for cytokeratin 18, either are associated with higher recurrence rates in colon and breast cancer or can be correlated to the prognosis of patients with gastric cancer. Technical aspects of surgery for hepatic, pulmonary and skeletal metastases are presented and discussed with respect to curative and palliative indications.
- 1 January 1995
- Vol. 120 (8) , 614-23
[An artificial liver on its way to clinical reality?].
Temporary extracorporeal liver assist devices based on liver cell cultures represent a promising approach for the treatment of liver failure as well as for perioperative care in liver surgery and transplantation. Primary hepatocytes from donor animals as well as human cell lines have been discussed as cell sources. A viable cell mass of 110-220 g (= 2.5-5 x 10(10) liver cells) has to be functionally active in bioreactors over a time period of several days. This cell number correlates to 10-20% of liver cells in an adult human liver. Neither in animal experiments, nor in clinical trials a complete liver replacement could yet be shown for cell-based bioreactors, however, beneficial effects have been demonstrated: partial detoxification and specific synthetic functions have been reported in animal experiments. Two authors have shown first preliminary clinical data on different cell-based liver assist devices with influences on blood parameters and the neurological status of treated patients. Nevertheless, clinical improvements also have been achieved by using non-biological support, like charcoal-hemoperfusion and modified hemodialysis. In order to assess the influence of liver support devices on better results in therapy of liver failure, randomized clinical trials have to be performed. Prior to this, artificial liver support systems have to demonstrate their biocompatibility and biosafety for clinical use as well as their efficacy and availability.
- 1 January 1995
- Vol. 120 (8) , 614-23
[An artificial liver on its way to clinical reality?].
Temporary extracorporeal liver assist devices based on liver cell cultures represent a promising approach for the treatment of liver failure as well as for perioperative care in liver surgery and transplantation. Primary hepatocytes from donor animals as well as human cell lines have been discussed as cell sources. A viable cell mass of 110-220 g (= 2.5-5 x 10(10) liver cells) has to be functionally active in bioreactors over a time period of several days. This cell number correlates to 10-20% of liver cells in an adult human liver. Neither in animal experiments, nor in clinical trials a complete liver replacement could yet be shown for cell-based bioreactors, however, beneficial effects have been demonstrated: partial detoxification and specific synthetic functions have been reported in animal experiments. Two authors have shown first preliminary clinical data on different cell-based liver assist devices with influences on blood parameters and the neurological status of treated patients. Nevertheless, clinical improvements also have been achieved by using non-biological support, like charcoal-hemoperfusion and modified hemodialysis. In order to assess the influence of liver support devices on better results in therapy of liver failure, randomized clinical trials have to be performed. Prior to this, artificial liver support systems have to demonstrate their biocompatibility and biosafety for clinical use as well as their efficacy and availability.
- 1 January 1994
- Published by Springer Nature
- p. 1274
Bausteine in der Entwicklung eines bioartifiziellen Leberersatzes
- 1 January 1994
- Published by Springer Nature
- p. 1274
Bausteine in der Entwicklung eines bioartifiziellen Leberersatzes
- 1 January 1993
- Vol. 118 (11) , 697-701
[Bio-artificial organ replacement of the liver].